Online citations, reference lists, and bibliographies.

Safety, Tolerability, And Pharmacokinetics Of 3 G Of Ceftolozane/Tazobactam In Healthy Adults: A Randomized, Placebo‐Controlled, Multiple‐Dose Study

Brian C. Yu, Adedayo Adedoyin, Ellie Hershberger, Luzelena Caro, Alan J. Xiao, Elizabeth G. Rhee, Jennifer A. Huntington
Published 2018 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Ceftolozane/tazobactam is an antibacterial approved at 1.5 g (1g/0.5 g) every 8 hours (q8h); higher doses may provide additional benefits in difficult-to-treat infections. We conducted a phase I trial in healthy adults evaluating safety, tolerability, and pharmacokinetics of 3 g (2 g/1 g) ceftolozane/tazobactam administered q8h for 10 days. Sixteen participants were randomized (2:1:1) to 3 g ceftolozane/tazobactam, 1.5 g ceftolozane/tazobactam, or placebo. Participants underwent regular safety and plasma drug level assessments, with a follow-up safety visit 7 days after completion. No adverse events (AEs) were reported with placebo; 75% of participants in the 1.5-g and 50% in the 3-g arm experienced AEs. AE types were similar between the ceftolozane/tazobactam groups; all AEs were mild. No participants experienced clinically meaningful laboratory assessment or electrocardiogram abnormalities. Both ceftolozane and tazobactam exhibited dose-proportional pharmacokinetics without accumulation and without substantial differences in clearance and volume of distribution between groups. In the 3-g group, mean ceftolozane parameters were: peak concentration 104 μg/mL (day 1), 112 μg/mL (day 10); half-life 3 hours (day 10); area under the concentration-time curve (AUC(0-t) ) 272 μg·h/mL (day 1), 300μg·h/mL (day 10). Mean tazobactam parameters were: peak concentration 28 μg/mL (day 1), 26 μg/mL (day 10); half-life 1 hour (day 10); AUC(0-t) 47μg·h/mL (day 1), 41μg·h/mL (day 10). Administration of 3 g ceftolozane/tazobactam q8h for 10 days was safe and well tolerated in healthy volunteers.
This paper references
10.1002/phar.1636
Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
Keith S Kaye (2015)
10.1093/cid/civ097
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Joseph S. Solomkin (2015)
Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.
Alfred S. Gin (2007)
Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
Craig W. McDonald (2016)
10.1016/j.ijantimicag.2014.01.032
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
David J. Farrell (2014)
10.1517/14740338.2012.643866
Adverse reactions to β-lactam antimicrobials
Philippe R. S. Lagacé-Wiens (2012)
10.1111/fcp.12227
Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects.
Anthony Aiudi (2016)
10.1002/phar.1653
Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.
Athena L. V. Hobbs (2015)
10.1097/CCM.0b013e318241e553
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Darren M. Roberts (2012)
10.1002/jcph.566
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia
Alan J. Xiao (2016)
10.1378/chest.10-2371
Antibiotic dosing in multiple organ dysfunction syndrome.
Marta Ulldemolins (2011)
10.1378/chest.11-1671
Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.
Andrew A Udy (2012)
10.1128/AAC.02310-13
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.
Brian D Vanscoy (2014)
10.1038/nrmicro862
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
George L. Drusano (2004)
10.5603/AIT.a2015.0082
A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
Jiřina Martínková (2016)
10.1186/cc9091
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
Fabio Silvio Taccone (2010)
10.2165/11594090-000000000-00000
Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid
Keith A. Rodvold (2011)
10.1016/S0140-6736(14)62220-0
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Florian M. E. Wagenlehner (2015)
10.1007/s40265-013-0168-2
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
George G Zhanel (2013)
10.1093/jac/dks246
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
Gurudatt Chandorkar (2012)
10.1086/344653
Prevention of resistance: a goal for dose selection for antimicrobial agents.
George L. Drusano (2003)
10.1128/AAC.01753-09
Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.
Yigong Ge (2010)
10.2215/CJN.05690611
Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis.
Johan M. Lorenzen (2012)
Adverse reactions to beta-lactam antimicrobials
P Lagace Wiens (2012)
Impli - cations of augmented renal clearance on drug dosing in critically ill patients : afocus on antibiotics
Hobbs ALV (2015)
tibiotic dosing in multiple organ dysfunction syndrome
M Ulldemolins (2011)
10.1093/jac/dku184
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Hélio Silva Sader (2014)
10.1128/AAC.00049-14
Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.
Christopher Lucasti (2014)
10.1586/14787210.5.3.365
Piperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combination
Alfred S. Gin (2007)
10.1002/jcph.395
Population Pharmacokinetics of Ceftolozane/Tazobactam in Healthy Volunteers, Subjects With Varying Degrees of Renal Function and Patients With Bacterial Infections
Gurudatt Chandorkar (2015)
10.1186/s13054-016-1255-z
Piperacillin concentration in relation to therapeutic range in critically ill patients – a prospective observational study
Johannes Zander (2016)
10.1592/phco.22.8.569.33209
Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
Myo-Kyoung Kim (2002)
10.1089/mdr.2015.0220
Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options.
Elizabeth A Cerceo (2016)
10.1128/AAC.05360-11
Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.
Marilyn N. Martinez (2012)
10.1016/S1473-3099(13)70190-7
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.
L Silvia Munoz-Price (2013)
10.1016/j.jcrc.2009.02.014
Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.
Anthony M. Nicasio (2010)
10.1186/cc12705
Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Mieke Carlier (2013)
10.1128/AAC.06349-11
Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.
Benjamin Miller (2012)
10.1378/chest.11-1671
Original ResearchCritical CareSubtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Andrew A Udy (2012)



This paper is referenced by
10.1016/S1473-3099(19)30403-7
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Marin H Kollef (2019)
10.1128/AAC.00344-19
Ceftolozane/Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.
Vidmantas Petraitis (2019)
10.1080/14656566.2020.1739269
An overview of ceftolozane sulfate + tazobactam for treating hospital acquired pneumonia.
Ibai Los-Arcos (2020)
10.1128/AAC.02578-18
Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
Kajal B. Larson (2019)
10.21037/atm.2018.10.29
New treatments of multidrug-resistant Gram-negative ventilator-associated pneumonia.
Garyphallia Poulakou (2018)
10.1093/jac/dkaa049
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia
Luzelena Caro (2020)
10.1016/j.cca.2018.10.034
Measurement of ceftolozane and tazobactam concentrations in plasma by UHPLC-MS/MS. Clinical application in the management of difficult-to-treat osteoarticular infections.
Raúl Rigo-Bonnin (2019)
10.1016/j.jiac.2018.11.005
Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
Makoto Kakara (2019)
Semantic Scholar Logo Some data provided by SemanticScholar